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Background: Mutant Ras oncogenes produce proteins that are unique to cancer cells and represent attractive
targets for vaccine therapy. We have shown previously that vaccinating cancer patients with mutant ras peptides is
feasible and capable of inducing a specific immune response against the relevant mutant proteins. Here, we tested
the mutant ras peptide vaccine administered in combination with low dose interleukin-2 (IL-2) or/and
granulocyte-macrophage colony-stimulating factor (GM-CSF) in order to enhance the vaccine immune response.
Methods: 5000 μg of the corresponding mutant ras peptide was given subcutaneously (SQ) along with IL-2
(Arm A), GM-CSF (Arm B) or both (Arm C). IL-2 was given SQ at 6.0 million IU/m2/day starting at day 5, 5 days/week
for 2 weeks. GM-CSF was given SQ in a dose of 100 μg/day one day prior to each ras peptide vaccination for 4 days.
Vaccines were repeated every 5 weeks on arm A and C, and every 4 weeks on arm B, for a maximum of 15 cycles
or until disease progression.
Results: We treated 53 advanced cancer patients (38 with colorectal, 11 with pancreatic, 1 with common bile duct
and 3 with lung) on 3 different arms (16 on arm A, 18 on arm B, and 19 on arm C). The median progression free
survival (PFS) and overall survival (OS) was 3.6 and 16.9 months, respectively, for all patients evaluable for clinical
response (n = 48). There was no difference in PFS or OS between the three arms (P = 0.73 and 0.99, respectively).
Most adverse events were grade 1-2 toxicities and resolved spontaneously. The vaccine induced an immune
response to the relevant ras peptide in a total of 20 out of 37 evaluable patients (54%) by ELISPOT, proliferative
assay, or both. While 92.3% of patients on arm B had a positive immune response, only 31% of patients on arm A
and 36% of patients on arm C had positive immune responses (P = 0.003, Fisher’s exact test).
Conclusions: The reported data showed that IL-2 might have a negative effect on the specific immune response
induced by the relevant mutant ras vaccine in patients with advanced cancer. This observation deserves further
investigations.
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Ras oncogenes are extensively characterized mutated
genes in human cancers [1,2]. With a single amino acid
substitution, the ras protein can potentiate transforming
capabilities in human cells [3]. Such point mutated Ras
genes have been found in a broad spectrum of human
malignancies, notably at codons 12, 13, and 61 [4].
Codon 12 mutations account for more than 90% of all
Ras mutations in human cancers [5]. Ras mutations are
prevalent in many types of tumors including pancreatic
(90%) [6], colorectal (50%) [7] and lung cancer (30%) [8].
Mutant ras peptides are processed and presented as for-
eign antigens by both MHC class I or II molecules
[9,10]. The products of mutant ras antigens represent at-
tractive targets for therapeutic cancer vaccines due to
their distinctive expression in tumor tissues as compared
to normal tissues. We and others have shown that vac-
cinating patients with mutant ras peptides could elicit
specific immune responses against the corresponding
antigens [11-14]. In a previously reported phase I clinical
trial, we demonstrated the safety of vaccinating advanced
cancer patients with the corresponding mutated ras pep-
tides [12]. In another study where patients were vac-
cinated in the adjuvant setting, the corresponding
mutated ras vaccines were capable of generating specific
immune responses with encouraging clinical outcomes
in colorectal and pancreatic cancer patients [15]. There-
fore, in an attempt to enhance the immune response
generated with our mutated ras peptide vaccine, we con-
ducted the current study where we combined this vac-
cine with interleukin-2 (IL-2), granulocyte-macrophage
colony-stimulating factor (GM-CSF) or both. This is
with the hope that the enhanced vaccine-induced im-
mune response may translate to an improved clinical
efficacy.
IL-2 plays a major role in enhancing the cytolytic ac-
tivity of T lymphocytes [16,17]. In addition, many inves-
tigators have shown that IL-2 can improve the immune
effect of cancer vaccines by potentiating the effect of
tumor-specific lymphocytes [18-20]. Based on this evi-
dence, we used low dose subcutaneous (SQ) IL-2 along
with the mutant ras peptide vaccine on one arm of the
study. GM-CSF is known to be an important element in
stimulating the growth of the antigen presenting cells
such as dendritic cells (DCs) [21]. In addition, GM-CSF
has been found to enhance the vaccine efficacy by in-
creasing the number of immature DCs (iDCs) at the vac-
cination site [22] and enhancing their maturation and
migration [23]. Accordingly, we used GM-CSF SQ along
with the ras vaccine in the second arm (arm B) of this
trial. Finally, patients in the third study arm (arm C) re-
ceived the ras vaccine in combination with both GM-
CSF and low dose SQ IL-2, which was supported by our
pre-clinical data showing a synergistic effect of thiscombination by inducing a larger number of cytotoxic T




The primary endpoint of this pilot study was to evaluate
the immune response generated with our ras peptide
vaccine admixed with Detox TM PC adjuvant when ad-
ministered with IL-2, GM-CSF or the combination of
both (IL-2 and GM-CSF). The secondary objectives were
to evaluate toxicities observed on each treatment arm,
and to explore clinical responses noted with our vaccin-
ation strategy.
Patient selection
Patients were assigned to three groups. All groups re-
ceived tumor-specific mutated ras peptide vaccine with
Detox™ PC admixture. The vaccine was given in combin-
ation with Il-2 (SQ) in arm A, GM-CSF (SQ) in arm B,
and both Il-2 and GM-CSF (SQ) in arm C. All study pa-
tients had histologically proven advanced solid tumors
expressing different Ras mutations and received multiple
lines of therapy. All enrolled patients met the protocol
eligibility criteria, including ECOG performance status
of 0-1 and life expectancy of more than 3 months. The
main exclusion criteria included evidence of brain me-
tastasis, history of autoimmune disease, and history of
other malignancies except basal carcinoma of the skin.
Both the National Cancer Institute (NCI) and National
Naval Medical Center (NNMC) Institutional Review
Boards (IRBs) approved the protocol, and the patients’
consent was obtained prior to enrollment.
Peptide selection
The peptides used in this study were 13-mer peptides
(residues 5-17) corresponding to the tumor Ras muta-
tions (Table 1). The Ras DNA mutations were deter-
mined by Restriction Fragment Length Polymorphism
(RFLP) and/or sequencing analysis of PCR amplified
DNA extracted from paraffin embedded tumor and/or
fresh tumor biopsy.
Peptide manufacturing and vaccine preparation
Synthesis of the peptides was done under contract with
Multiple Peptide Systems (San Diego, CA) for clinical
use. The vaccine contained the peptide and Detox™ PC
as an adjuvant. The vaccine was prepared in the follow-
ing manner: the pharmacist calculated the volume corre-
sponding to 120% of the dose of ras peptide. Sterile
water (0.48 ml) was then added to a vial containing 0.12
ml Detox PC to bring the final vaccine volume to 0.6 ml.
The sterile water/Detox PC emulsion was shaken. The
appropriate ras peptide was added to the resulting
Table 1 Ras peptides used for vaccination
Ras
peptides
Amino acid sequence Vaccinated patients by arm
5 6 7 8 9 10 11 12 13 14 15 16 17
ras 5-17 Lys- Leu-Val- Val- Val- Gly- Ala- Gly- Gly- Val- Gly- Lys- Ser Nome
(wild type)
ras 5-17 Lys- Leu-Val- Val- Val- Gly- Ala- Asp- Gly- Val- Gly- Lys- Ser A: 1-4, 9-12, 14, 16
(Gly→Asp) B: 3-6, 8-10, 14-16
C: 1-5, 7, 9-11, 13-19
ras 5-17 Lys- Leu-Val- Val- Val- Gly- Ala- Val- Gly- Val- Gly- Lys- Ser A: 5, 6, 15
(Gly→Val) B: 1, 7, 11, 12, 17, 18
C: 6, 12
ras 5-17 Lys- Leu-Val- Val- Val- Gly- Ala- Cys- Gly- Val- Gly- Lys- Ser A: 7, 8, 13
(Gly→Cys) B: 2, 13
C: 8
The peptides used in the study were 13-mer peptides (residues 5-17) corresponding to the tumor Ras mutations. Corresponding mutant part of the peptide
is bolded.
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texed (not shaken) for 15-30 seconds. The product was
labeled with the peptide, concentration, time of prepar-
ation, and “one hour expiration”. 1.5 ml of the admixture
was used for the patient’s vaccination.
Vaccine administration
All study patients were assigned to one of three treat-
ment arms. Patients in all treatment groups received
specific mutated ras peptide vaccine with admixture of
Detox™ PC adjuvant administered SQ. In addition, arm
A patients received IL-2 (SQ), arm B patients received
GM-CSF (SQ), and arm C patients received both IL-2
and GM-CSF (SQ).
All patients received 1.5 ml of the vaccine solution
with one half of the total dose administered into each of
two sites, over the deltoids, the thighs, or the abdomen
(0.75 ml/site). Vaccination was repeated every 5 weeks
on arm A and C, and every 4 weeks on arm B for a total
of 3 vaccinations. Patients continued to receive sets of 3
additional vaccinations for a total of 15 vaccinations as
long as they demonstrated lack of disease progression.
After receiving the vaccine, patients were observed in
the outpatient clinic for any acute hypersensitivity reac-
tion. IL-2 was administered SQ in a dose of 6.0 million
IU/m2/day starting 4 days after vaccination, 5 days/week
for 2 weeks in the arms, abdomen, or thighs. The initial
IL-2 dose was administered in the outpatient clinic with
subsequent injections were done via self-administration
by the patient on an outpatient basis. GM-CSF was given
SQ starting one day prior to the vaccination and contin-
ued for 4 days at a dose of 100 μg/day. GM-CSF was ad-
ministered at two separate sites, 50 μg per site, at the
same sites of the vaccine injection. The GM-CSF was
administered in the outpatient clinic directly after thepeptide injection but with a separate syringe. Patients
were monitored for any hypersensitivity reaction.
Clinical monitoring
Patients were evaluated for toxicity and tumor response
during treatment. Tumor response was assessed by
physical exam and CT scan according to RECIST criteria
at baseline, after each set of 3 vaccinations, and every 2
months during follow-up. Patients were taken off study
due to either deterioration in performance status, disease
progression or request to withdraw from the study. Dis-
ease progression was defined according to the modified
WHO criteria of progression as the appearance of new
lesions and/or a 25% increase of measurable lesions as
evident by CT scan. Once patients had progressed,
follow-up was not required except to document late tox-
icities and death. Adverse events and toxicities were de-
fined and graded according to the NCI Common
Toxicity Criteria.
Immune monitoring
Peripheral blood mononuclear cells (PBMCs) were col-
lected within 1 hour prior to every vaccination and every 2
months during follow-up. PBMCs were isolated from hep-
arinized venous blood by Ficoll Hypaque centrifugation,
washed, and cryopreserved in 2-mL vials, using a CryoMed
freezer. The immunological response was assessed by
in vitro T cell proliferation assay and enzyme-linked im-
munosorbent spot (ELISPOT) assay before and after each
vaccination.
In vitro T cell proliferation assay
The patient’ PBMCs were incubated in vitro with the ap-
propriate tumor-specific ras peptide and evaluated for
peptide-induced proliferation following up to 5 days of
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final 18-24 hours of their culture. Proliferation was mea-
sured and quantified by the incorporation of [3H]-thymi-
dine. Positive control included cells pulsed with a recall
antigen peptide (influenza matrix 58-66, GILGFVFTL). A
proliferation of more than two fold above the control of
the wild-type ras peptide at 2 time points was considered
as a positive response.
ELISPOT assay
All ELISPOT assays were performed at the Laboratory of
Cell-Mediated Immunity, SAIC-Frederick (CLIA-certified
lab). Two frozen normal donor controls with known re-
sponsive values were run with each assay to assure quality
control of the assay results. For all assays, at least one of
the two controls was within 2 standard deviations of the
laboratory-generated means for CMV and CEF. All assays
were performed on 7-8 day in vitro stimulated PBMCs
(100 K/well) as the effectors and peptide-pulsed autolo-
gous PBMCs (100 K/well) as the antigen presenting cells
(APCs). When possible, PBMCs from the earliest time
point were used as the APCs. However, if this was not
possible, the pulsed PBMCs were assayed alone to make
sure they were not producing any spots. Briefly, the
day before assay setup, 96-well polyvinylidene fluoride
(PVDF) membrane, HTS opaque plates (Millipore, Billerica,
Massachusetts, MSIPS4W10) were coated overnight with
a 1:100 dilution of anti-human IFN-γ capture antibody
(1mg/mL, Mabtech Inc., Mariemont, OH, Cat# 3420-3-
1000) in Dulbecco's phosphate buffered saline (DPBS) at
room temperature. Antibody-coated plates were washed
four times in DPBS the next day and blocked with 5% hu-
man AB ELISPOT medium at 37°C for approximately 2
hours. 1 × 105 in vitro stimulated PBMCs and 1 × 105 au-
tologous, peptide-pulsed PBMCs were plated per well.
The plates were incubated for 18-20 hours at 37°C. The
next day, the plates were manually washed six times with
0.05% Tween 20 in DPBS, followed by a 2-hour incubation
at room temperature with a 1:2000 dilution of the biotiny-
lated secondary antibody, anti-human IFN-γ (1 mg/mL
Mabtech Inc., Mariemont, OH, Cat# 3420-6-1000) in
DPBS/1% bovine serum albumin/0.05% Tween. After incu-
bation and four washes in DPBS to remove excess anti-
body, a 1:3000 dilution of streptavidin alkaline phosphatase
(Mabtech, Mariemont, OH, Cat# 3310-10) in DPBS/1%
bovine serum albumin, was added to each well for 1 hour
at room temperature followed by 4 manual washes in
DPBS. Finally, the BCIP/NPT substrate, 100 μl/well,
(KPL, Gaithersburg, Maryland, Cat# 50-81-08) was
added for 7-10 minutes, resulting in the development of
spots. The reaction was stopped by washing three times
in distilled water. Plates were dried overnight and the
spots were visualized and counted using the Immuno-
Spot Imaging Analyzer system (Cellular TechnologyLtd., Cleveland, OH). ELISPOT results were expressed
as the “number of spots per 106 responder cells” after
subtracting background spots obtained in wells of effec-
tors with non-pulsed PBMCs. For each subject, PBMCs
obtained before and after vaccination were analyzed in
the same assay to avoid inter-assay variability. An in-
crease of number of spots to more than two fold above
the control of the wild-type ras peptide or the irrelevant
TAX peptide at 2 time points was considered as a posi-
tive response.
Regulatory T cells (T-regs)
Cryopreserved PBMCs were thawed rapidly at 37°C. The
cells were transferred into 15 mL conical tubes (Corning,
Lowell, MA) and diluted to 10 mL by dropwise addition of
RPMI medium containing 20% FBS. The cells were pel-
leted by low-speed centrifugation at 250 × g for 10 min at
25°C. Supernatants were discarded and cell pellets resus-
pended in 5 mL of DPBS containing 2% (huAB) serum to
block cell surface Fc receptors. The samples were mixed
briefly and incubated on ice for 15 minutes. Following in-
cubation the cells were pelleted by centrifugation as de-
scribed before, washed two times with DPBS containing
2% bovine serum albumin (BSA; DPBS/2% BSA) and re-
suspended in 1 mL of DPBS/2% BSA. The cells were
counted in a Coulter counter and adjusted to a final con-
centration of 10 × 106/mL in DPBS/2% BSA. The cells
(1 × 106/tube) were stained for surface markers (CD25,
CD3, and CD4) for 20 minutes at room temperature (RT)
in the dark and washed two times with DPBS/2% BSA.
Intracellular staining for FoxP3 was carried out using hu-
man FoxP3 buffer prepared as described by the manufac-
turer (BD BioSciences, San Jose, CA). Briefly, following
staining of surface antigens, cells were resuspended in 2
mL of fixing solution (buffer A) and incubated for 10 mi-
nutes at RT in the dark. Cells were washed two times with
PBS/2% BSA, resuspended in 0.5 mL permeabilization so-
lution (buffer C) and incubated for 30 minutes at RT in
the dark. Cells were washed two times in PBS/2% BSA
and stained with anti-human FoxP3 antibody for 30 mi-
nutes at RT in the dark. Cells were then washed two times
and resuspended in 0.5 mL of PBS/2% BSA for four-color
flow cytometric analysis using the FACSCanto cytometer
(BD BioSciences, San Jose, CA) running FACS Diva acqui-
sition software (version 6.0). Each assay contained a paral-
lel set of cells stained with relevant isotype controls (Alexa
Fluor 488 IgG1 and PE IgG1). Flow cytometric data ana-
lysis was carried out using FlowJo Software. T cells were
identified by plotting CD3 by side scatter. CD4+ T cells
were identified by further gating the CD3+ subset by for-
ward and side scatter and by CD4. The regulatory CD4+
T cell subset was identified by plotting CD25 versus FoxP3
with the quadstat setting determined based on the isotype
control tube. The quadrant markers of the CD25 versus
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each case the pre-vaccination sample and the post 4 or
8-vaccination sample (based on how many vaccines the
patient received) were tested side by side in the same ex-
periment and were done from frozen samples. This testing
strategy was used to minimize variability from day to day
in staining or thawing. The samples were tested in 4 inde-
pendent setups over 3 days. We have included 2 internal
controls in each experiment, one of those being a frozen
leukapheresis sample that was included in each test run as
a measure of interassay reproducibility.Statistical analysis
Actuarial analyses were performed on the survival and
progression free survival (PFS) data, starting at the on-
study date, or the date of progression when determining
probability of survival following progression, using the
Kaplan-Meier method. Curves were compared using the
log-rank test. Survival and PFS times were censored if
the patient was alive and/or without progression as ap-
propriate at the last follow-up date. The fractions of pa-
tients with immune responses on the three arms were
compared using Mehta’s modification to Fisher’s exact
test [25]. All reported P values are two-tailed, and un-
adjusted for multiple comparisons.Table 2 Arm A (vaccine + IL-2): patient profiles, clinical, and im






1A 56 Colon IV 2 PD 0.5
2A 57 Colon IV 3 PD 3.9
3A 62 Colon IV 3 PD 5.8
4A 50 Pancreatic IV 3 PD 3.6
5A 60 Lung IV 1 PD 1
6A 59 Colon IV 3 PD 3.5
7A 52 Colon NED 11 Completed 12
8A 68 Lung IV 3 PD 3.6
9A 56 Colon NED 10 PPS 18
10A 63 Colon IV 3 PD 3.3
11A 42 Pancreatic NED 6 PD 7.5
12A 39 Colon NED 3 PD 6.2
13A 67 Colon IV 3 PD 3.5
14A 51 Colon NED 3 PD 7.1
15A 60 Pancreatic IV 3 PPS/Lost to follow-up 2.7
16A 61 Colon IV 3 PD 3.6
#Progression free survival was calculated as time from the date the consent was sig
(+). *Overall Survival was calculated as time from consent date until death or last fo
sample not available. Immune response was marked as negative (-) or positive (+) a
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Per
Survival, ms Months.Results
Patient profiles
Fifty-three patients were enrolled on this trial (16 on
arm A, 18 on arm B, and 19 on arm C). Patient charac-
teristics are summarized in Table 2, Table 3, Table 4. Age
of the patients ranged from 33 to 79 years with a mean
of 55.3 years (standard deviation of 10.7 years). The ma-
jority of the patients, 38 out of the 53 enrolled, had colo-
rectal cancers (11 on arm A, 12 on arm B and 15 on
arm C), eleven patients had pancreatic cancer (3 on arm
A, 5 on arm B and 3 on arm C), three patients had lung
cancer (2 on arm A and 1 on arm C), and one patient
on arm B had cancer of the common bile duct. All pa-
tients had adenocarcinoma except for one who had
poorly differentiated non-small cell carcinoma of the
lung (3C). All patients’ tumors harbored Ras mutations
as follows: the majority of patients (36 patients) had a
glycine to aspartic acid substitution and the rest had ei-
ther a glycine to valine (11 patients) or a glycine to cyst-
eine (6 patients) substitution. All patients were heavily
pretreated. Most underwent at least one surgical resec-
tion except for two patients on each arm (5A, 6A, 4B,
18B, 3C, 19C). At least one chemotherapy regimen was
administered to all patients except for one (16C). In
addition, 39 of the 53 patients received 2 or more







Pre-vaccine Post-vaccine Pre-vaccine Post-vaccine
5.5 ND
16.8 NA - -
21.5 - - - -
6.2 - - - -
2.8 ND
8.9 NA
9+ 129+ - + - +
13.1 - - - -
.8 37.2 - + - +
19.9 - - - -
24.1 - - - -
23 - - - -
4.8 - + + +
41.3 - - - -
+ 5.3 NA - -
17.3 - + - -
ned until evidence of disease progression or last follow-up without progression
llow-up (+). ND, not done because patient received 2 or less vaccines; NA,
s described in the manuscript.
formance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall
Table 3 Arm B (vaccine + GM-CSF): patient profiles, clinical data, and immunological outcomes










Pre-vaccine Post-vaccine Pre-vaccine Post-vaccine
1B 55 Biliary NED 3 PD 2.9 8.7 + + + +
2B 33 Colon IV 3 PD 2.9 16.9 - + NA
3B 51 Colon IV 5 PPS/Lost to follow-up 9.2+ 52.6 + + - +
4B 48 Pancreatic NED 13 Completed 35.4+ 35.4 - + - -
5B 51 Colon IV 1 PD 1 1.5 ND
6B 38 Colon IV 1 Refused further Tx 0.2+ 8.3 ND
7B 60 Pancreatic IV 3 PD 4.6 21 - - NA
8B 57 Colon IV 3 PD 3.1 6.8 NA
9B 52 Colon IV 3 PD 3.3 28.3 - + + +
10B 58 Pancreatic IV 3 PD 2.9 20.9 + + - +
11B 45 Pancreatic IV 2 PD 1 7.3 ND
12B 79 Colon IV 3 PPS 12.9 42.1 - + - +
13B 43 Colon IV 3 PD 2.6 6.3 - - - +
14B 78 Colon NED 8 Left voluntarily 16.8 69 - + - +
15B 63 Colon IV 3 PD 2.8 11.6 + + - +
16B 64 Colon IV 6 PD 5.7 20.7 - + - -
17B 71 Colon IV 6 PD 5.6 25.9 - + - +
18B 58 Pancreatic IV 2 PD 2.6 3.3 ND
#Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression
(+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA,
sample not available. Arm B (Vaccine + GM-CSF): Patient Profiles, Clinical Data, and Immunological Outcomes.
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall
Survival, ms Months.
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apy. Twelve patients were enrolled on the trial with no
evidence of disease following resection of their primary
or metastatic disease: 5 patients on arm A (7A, 9A, 11A,
12A, 14A), 3 patients on arm B (1B, 4B, 14B) and 4 pa-
tients on arm C (2C, 11C, 13C, 15C) (Table 2, Table 3,
Table 4).
Safety and toxicity
The vaccine was well tolerated for all arms. The majority
of toxicities were grade 1 or 2, with fatigue, fever and
local site reaction being the most common, accounting
for 77%, 71%, and 69% of patients, respectively. The
most common treatment-related grade 3 toxicities were
fatigue (5.7%), followed by diarrhea (3.8%), vomiting
(3.8%), and transaminitis (3.8%) (Table 5). The majority
of these toxicities were determined to be related to IL-2
or GM-CSF and resulted in dose reduction in some
cases. IL-2 was dose reduced to 50% in 3 patients, 1 pa-
tient on arm A (7A) and 2 patients on arm C (5C, 6C).
On the other hand, only two patients had 50% dose re-
duction for GM-CSF, both on arm B (7B, 9B). Grade 4
treatment-related toxicity occurred in only one patient(3A) who developed myocardial infarction that was de-
termined to be possibly related to IL-2. Treatment was
discontinued for that patient.
Clinical response
Five patients were excluded from the clinical response
analyses since they received less than 2 vaccines. They
were removed from the study due to early disease pro-
gression (5A, 5B, and 7C), poor performance status
(3C), or refusal of further treatment (6B). Therefore, the
clinical response was evaluable in only 48 of the 53
treated patients. Of these, 37 had progression of disease
during the course of treatment (12 patients on each of
arm A and B, and 13 on arm C). Five patients had stable
disease (one patient on arm A and 2 patients on each of
arm B and C). Six patients remained with no evidence of
disease (2 on each arm); interestingly, 4 out of these 6
patients completed the study after they received 11-15
vaccines (7A, 4B, 2C, 11C) (Table 2, Table 3, Table 4).
For the full cohort (n = 48), the median progression free
survival (PFS) and overall survival (OS) was 3.6 and
16.9 months, respectively (Figure 1). Patients on arm A
had a median PFS and OS of 3.9 and 17.3 months,
Table 4 Arm C (vaccine + IL-2 + GM-CSF): patient profiles, clinical data, and immunological outcomes











1C 40 Rectal IV 15 PD 26.5 80.4 NA +
2C 59 Colon NED 14 Completed 110.2+ 110.2+ - -
3C 58 Lung III 1 PPS 8 72.8 ND
4C 35 Colon IV 6 PD 6.9 18.7 - -
5C 52 Rectal IV 3 PD 3.2 6.4 - -
6C 36 Rectal IV 2 PPS/Lost to follow-up 2+ 9.2 ND
7C 75 Colon IV 1 PD 0.9 5.2 ND
8C 49 Colon IV 3 PD 3.5 5.5 - -
9C 42 Colon IV 3 PD 4 7.6 - -
10C 48 Colon IV 2 PD 1.7 4.7 ND
11C 48 Rectal NED 15 Completed 120.4+ 120.4+ - +
12C 54 Colon IV 3 PD 3.6 26.6 + +
13C 57 Colon NED 3 PD 3.6 9.1 NA
14C 66 Pancreatic IV 2 PD 2.4 2.8 ND
15C 56 Rectal NED 4 PD 3.6 28.5 - +
16C 73 Pancreatic IV 3 PD 3.6 6.6 - -
17C 51 Colon IV 2 PD 1.9 7.9 ND
18C 57 Colon IV 3 PPS 4.4 9.8 - -
19C 66 Pancreatic IV 2 PD 2.1 2.7 ND
#Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression
(+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA,
sample no available. Immune response was marked as negative (-) or positive (+) as described in the manuscript.
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall
Survival, ms Months.
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OS of 3.2 and 20.8 months, respectively, and patients on
arm C had a median PFS and OS of 3.6 and 9.1 months,
respectively (Figure 1). The difference in PFS or OS be-
tween arms A, B and C was not statistically significant
(P = 0.74 and 0.99, respectively). Finally, we conductedTable 5 Grade 3-4 vaccine-related toxicities




Increased transaminase 2 0
Local site reaction 1 0
Fever 1 0
Myalgia 1 0
Generalized rash 1 0
Myocardial infarction* 1 1
*Grade 4 Toxicity.
All grade 3 toxicities were reported for the full cohort and per arm. Only one gradean unplanned subgroup analysis for patients with stage
IV advanced colorectal cancer (n = 26) since they repre-
sent the majority of patients treated on the three arms.
We found that patients with advanced colorectal cancer
had a median PFS and OS of 3.5 and 14.2 months,










4 toxicity of myocardial infarction was reported in one patient (3A).
Figure 1 Clinical outcome. Kaplan-Meier curves for progression free survival (PFS) and overall survival (OS) for the full cohort (A, B), per arm
(C, D), and based on immune response (E, F).
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Immune response assays
Immune assays were planned to be performed only in
patients who received 3 vaccines or more, a total of 40
patients (14 on each of arm A and B, and 12 on Arm C).
However, blood samples were not available in 3 out of
these 40 patients (one on each arm: 6A, 8B, and 13C).
Therefore, immune responses were measured in a total
of 37 patients (13 on each of arm A and B, and 11 on
arm C). Immune responses were measured using either
ELISPOT, proliferative assay, or both in Arms A and B,
and ELISPOT only in Arm C given the limited sample
availability (Table 2, Table 3, Table 4). Immune response
was considered positive if either one of the performedassays was positive. Only 7 out of 37 patients (19%)
demonstrated a baseline endogenous immune response
to the corresponding ras peptide by ELISPOT, prolifera-
tive assay, or both (1 on each of arm A and C and 5 on
arm B). Overall, a total of 20 out of 37 evaluable patients
(54%) had positive immune responses by ELISPOT, pro-
liferative assay, or both. There were significant dif-
ferences in immune responses generated on each arm
(P =0.003, Mehta’s modification to Fishers exact test).
While 12 out of 13 evaluable patients (92.3%) on arm B
had positive immune responses, only 4 out of 13 evalu-
able patients (31%) on arm A and 4 out of 11 evaluable
patients (36%) on arm C had positive immune responses
(Table 2, Table 3, Table 4). Interestingly, the positive
Rahma et al. Journal of Translational Medicine 2014, 12:55 Page 9 of 12
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proliferation responses in all patients evaluated by both
assays except one (13B); on the other hand, 3 patients
with positive T cell proliferation responses had negative
ELISPOT responses (16A, 4B, and 16B). Such an associ-
ation could not be ascertained on arm C since only ELI-
SPOT data was available. Figure 2 shows examples of
three patients with positive immune response, one on
each arm (Patients# 7A, 14B, and 11C).
T-regulatory cells (T-reg) analysis
T-regs (CD4 + CD25 + FoxP3+) were measured in the
peripheral blood pre-vaccination and post 4 or 8 vacci-
nations in 11 patients only, due to the limited availability
of blood samples (3 patients on Arm A and 4 patients
on each of Arm B and C). An increase in T-regs was
defined as an increase in the frequencies of post-
vaccination T-regs by at least 25% compared to pre-
vaccination. Interestingly, all tested patients on Arm B























Figure 2 Immune responses measured by ELISPOT assay and In vitro
14 B (panel C), and 11C (panel E) who had positive immune responses to
peptide in red and the control peptide (tax) in green. Panels B and D show
14B, respectively in blue compared with the normal ras peptide in red and
Pre-vaccine, Pre-vaccination sample; Post-V, Post-vaccination sample marke
(ms) from the last post vaccine sample.vaccination samples compared with pre-vaccination
samples, while none of the tested patients on arm C and
one out of 3 tested patients on arm A had an increase in
T-reg frequencies (Figure 3).
Clinical and immune response correlation
We performed a survival analysis based on the resulting
immune responses. Only patients with available immune
response data (n = 37) were included in this analysis,
whereas in the previous clinical response analysis there
were 48 patients included; thus, 23% of the data were
missing in this analysis (11/48). First, we performed this
clinical-immune response survival analysis by arm (A
(n = 13), B (n = 13), C (n = 11)). We found no evidence
for an immune response effect for either OS or PFS, by
arm. Second, we performed the same analysis for the full
cohort (n = 37). We found a weak immune response ef-
fect with respect to OS and no evidence for an immune
response effect with respect to PFS for the full cohort.




















































































T cell proliferation assay. ELISPOT results for patient 7A (panel A),
the mutant ras peptide in blue compared with the normal ras
positive T cell proliferative assay responses for patient 7A and
the positive control peptide (influenza) in green. Abbreviations:





































Figure 3 Regulatory T cells (T-regs). The percentage of T
regulatory cells (CD4 + CD25 + FoxP3+) measured in the peripheral
blood of selected patients on Arm A (7A, 9A, 11A) marked in blue
colors, B (4B, 14B, 16B, 17B) marked in red colors, and C (1C, 2C, 4C,
11C) marked in green colors. Samples were taken pre-vaccination
and post-vaccine #4 and #8.
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compared to a median PFS of 4.2 months (P = 0.43) and a
median OS of 16.8 months for patients with a negative im-
mune response (n = 17, P = 0.038) (Figure 1). However,
when we performed a stratified test to compare the im-
mune response curves while controlling for the effect of
the three arms (n = 37); the P values were 0.086 and 0.15
for OS and PFS, respectfully, consistent with no evidence
for an immune response effect with respect to OS and
PFS.
Discussion
In this pilot study, we evaluated the feasibility, safety
and immune response generated with our mutant ras
peptide vaccine when administered in combination with
either low dose SQ IL-2, GM-CSF or both cytokines. All
vaccine combinations were well tolerated with a compar-
able safety profile within all treatment arms. 54% of pa-
tients generated an immune response against the relative
mutated peptide vaccine with a significant difference be-
tween the 3 arms; 92% of patients on arm B, 31% on
arm A and 36% on arm C had positive immune re-
sponses (P = 0.003).
The mutant ras peptides have been investigated as
cancer vaccines in several clinical trials alone [14,26] or
in combination with GM-CSF [13,27,28]. Carbone et al.
treated 21 patients who had various stages of colon, pan-
creatic and lung cancer with 17-mer peptides corre-
sponding to the tumor’s mutation and demonstrated a
median OS of 3.8 months and an immune response
against the mutant ras peptide in 38% of patients as
measured by ELISPOT [14]. Gjertsen et al. vaccinated
38 patients who had advanced pancreatic cancer with a
mixture of 4 mutant ras peptides reflecting the substitu-
tion of Gly at position 12 with an Asp, Cys, Val or Arg
residue in combination with GM-CSF and reported amedian OS of 2.7 months and peptide-specific immunity
of 58% as measured by DTH and T-cell response [13].
The patient population on these trials is comparable to
ours, given their advanced disease and the prior treat-
ment they received. However, the majority of patients on
our trial had colorectal cancer and also had a longer
period of follow-up (up to 120.4 months). It is difficult
to compare the immune response elicited by the ras pep-
tide on this trial to the others due to the variability of im-
mune assays used in these trials and the lack of their
validation as a measurement of immune response [29].
Interestingly, all evaluable patients but one developed
an immune response against the corresponding ras pep-
tide administered in combination with GM-CFS only in
arm B (92%). In contrast, the ras peptide failed to induce
an immune response in the majority of patients who re-
ceived IL-2 with or without GM-CSF (immune response
of 31% on arm A and 36% on arm C). We and others
have shown that the administration of IL-2 could lead to
the expansion of T-regs in vitro and in vivo and there-
fore, to the inhibition of an immune response [18,30].
Whether the negative IL-2 effect on immune response
in this trial was mediated by T-reg expansion could not
be determined due to the limited available samples
tested for T-regs.
Although this trial was not designed primarily to test
for clinical efficacy, the median PFS and OS for the full
cohort (3.6 and 16.9 months, respectively) was encour-
aging, given the fact that the majority of these patients
had advanced disease on enrollment and were heavily
pretreated. In addition, in an unplanned subgroup ana-
lysis of patients with advanced stage IV colorectal cancer,
we found that this heavily pretreated cohort had a me-
dian PFS of 3.5 and OS of 14.2 months compared to a
historical control of 7.3 and 12.9 months, treated with
the best available standard therapy [31]. Interestingly, al-
though patients treated on this trial had a shorter me-
dian time to progression, they had a slightly longer
median OS compared to historical control. Accordingly,
we calculated “the post progression survival (PPS)”, de-
fined as time from progression to death, for patients
with advanced stage IV colorectal cancer treated on our
trial. We found the median PPS for patients with ad-
vanced stage IV colorectal cancer in our trial to be not-
ably longer compared to the historical control (10.3
months vs. 5.6 months). This observation correlates with
the recently published proposed model by Stein et al.,
which suggested that tumor growth rate decreased more
with vaccine therapy compared to chemotherapy, leading
to a longer survival despite an early progression of disease
[32]. This is in correspondence with the revised immune
RECIST criteria and the recently published “FDA Guid-
ance for Industry Clinical Considerations for Therapeutic
Cancer Vaccines” [33,34]. Indeed, the long follow-up time
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allowed us to perform such analysis, although we realize
that our analysis is limited by the small number of patient
sample and the various therapies that the patients received
post-vaccination. We and others have shown that patients
who generate a T-cell immune response are more likely to
have longer survival compared to non-immune responders
[18,35,36]. In this trial, although we found a weak evidence
for an immune response effect with respect to OS (P =
0.038), this effect was weaker when the effect of the three
arms was taken into consideration (P = 0.086). Indeed, the
amount of missing immunological data precludes a mean-
ingful conclusion of the association between immunologic
and clinical data in this trial.
Conclusions
In summary, our trial confirmed the feasibility and safety
of using mutant ras peptide vaccine as a personalized
treatment for patients with advanced cancers. Indeed,
these mutant ras vaccines were shown to be capable of
generating a specific immune response against the rele-
vant peptide. Further studies are needed to test whether
IL-2 is detrimental to cancer vaccines, given the lower
immune response rate in patients who received it. None-
theless, although not powered to test for clinical efficacy,
our study finding correlates with the observations of
others indicating that cancer vaccines could lead to lon-
ger survival, despite early progression of disease.
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